



*Advances in Chronic Kidney Disease* (ISSN 1548-5595) is published bi-monthly by Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169. Months of issue are January, March, May, July, September, and November. Business and Editorial Offices: 1600 John F. Kennedy Blvd., Ste. 1800, Philadelphia, PA 19103-2899. Elsevier Health Sciences Division Subscription Customer Service: 3251 Riverport Lane, Maryland Heights, MO 63043. Periodicals postage paid at New York, NY and additional mailing offices.

**POSTMASTER:** Send address changes to *Advances in Chronic Kidney Disease*, 3251 Riverport Lane, Maryland Heights, MO 63043.

**Editorial correspondence** should be addressed to Charuhas V. Thakar, MD, Professor of Medicine, Director, Division of Nephrology, Kidney C.A.R.E. Program, ML 0585, 231 Albert B Sabin Way, Cincinnati, OH 45267; email: [thakarcv@ucmail.uc.edu](mailto:thakarcv@ucmail.uc.edu).

**Correspondence** regarding subscriptions or change of address should be directed to the Publisher, Elsevier, Periodicals Department, 3251 Riverport Lane, Maryland Heights, MO 63043.

**Change of address notices**, including both the old and new addresses of the subscriber and the mailing label, should be sent at least one month in advance.

**Customer Service:** (800) 654-2452 (United States and Canada); (314) 447-8871 (outside United States and Canada). Fax: (314) 447-8029. E-mail: [journalscustomer-service-usa@elsevier.com](mailto:journalscustomer-service-usa@elsevier.com) (for print support); [journalsonlinesupport-usa@elsevier.com](mailto:journalsonlinesupport-usa@elsevier.com) (for online support).

Subscriptions are available on a calendar-year basis. Single issues are available on request from your nearest Regional Sales Office. All prices include postage. Personal rates apply only when issues of the journal are sent to a private address and payment is made by personal check or credit card. Please visit our Support Hub page <https://service.elsevier.com> for assistance.

Copyright © 2022 National Kidney Foundation, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means now or hereafter known, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher. Printed in the United States of America.

Permission may be sought directly from Elsevier's Global Rights Department in Oxford, UK: phone 215-239-3804 or +44 (0) 1865 843830, fax +44 (0) 1865 853333. Requests may also be completed online via the Elsevier site (<http://www.elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material>).

The appearance of the code at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copy-

right Clearance Center, Inc. (222 Rosewood Drive, Danvers, MA 01923; (508) 750-8400; [www.copyright.com](http://www.copyright.com)). This consent is given on the condition that the copier pay the stated per-copy fee for that article through the Copyright Clearance Center, Inc. for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Absence of the code indicates that the material may not be processed through the Copyright Clearance Center, Inc.

**Reprints:** Reprint inquiries should be addressed Derrick Imasa, Elsevier Inc., Commercial Reprints, 230 Park Avenue, Suite 800, New York, NY 10169. Telephone (212) 633-3874, fax (212) 633-3820; e-mail: [d.imasa@elsevier.com](mailto:d.imasa@elsevier.com).

**Advertising representative:** Jane Liss, Triple Threat Media, 630 Madison Ave, Manalapan, NJ 07726. Telephone: (732) 890-9812.

The ideas and opinions expressed in *Advances in Chronic Kidney Disease* do not necessarily reflect those of the National Kidney Foundation, the Editor, or the Publisher. Publication of an advertisement or other product mentioned in *Advances in Chronic Kidney Disease* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The National Kidney Foundation and the Publisher do not assume any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications.

**Notice:** Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.

The contents of *Advances in Chronic Kidney Disease* are indexed in MEDLINE®/PubMed, Current Contents Connect, Science Citation Index, EMBASE, Scopus, and CINAHL.

The *Advances in Chronic Kidney Disease* homepage is located at [www.ackdjournal.org](http://www.ackdjournal.org).